Articles From: Arrowhead Announces Pricing of Underwritten Offering of Common Stock to Art's Way Manufacturing Announces Their Wholly Owned Subsidiary, Art's Way Scientific, Has Been Awarded A New Contract with A Leading Upper Midwest Dairy Operation For Three Modular Calf Care Buildings.


2014/2/19
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock, offered at a price of $18.95 per share.
Sign-up for Arrowhead Announces Pricing of Underwritten Offering of Common Stock investment picks
2014/2/18
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement.
Sign-up for Arrowhead Announces Proposed Underwritten Offering of Common Stock investment picks
2014/3/24
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection.
Sign-up for Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients investment picks
2013/10/14
Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on October 11, 2013 it closed a previously announced private offering of common and convertible preferred stock.
Sign-up for Arrowhead Closes Private Offering with Net Proceeds of $60 Million investment picks
2014/2/24
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on February 24, 2014 it closed the previously announced underwritten offering of 6,325,000 shares of common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 825,000 additional shares.
Sign-up for Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million investment picks
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.
Sign-up for Arrowhead Completes Enrollment in Phase 1 Study of ARC-520 for the Treatment of Chronic Hepatitis B investment picks
2014/4/1
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection.
Sign-up for Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520 investment picks
2014/2/21
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received notice that the NASDAQ Listing Qualifications Department has approved an application to upgrade the listing of the Company’s securities from the NASDAQ Capital Market to the NASDAQ Global Select Market, effective with the opening of business on February 21, 2014.
Sign-up for Arrowhead Listing Upgraded to NASDAQ Global Select Market investment picks
2013/12/9
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company’s clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.
Sign-up for Arrowhead Presents Phase 1 Data on ARC-520 at HepDART 2013 investment picks
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has priced a private offering with net proceeds expected to be $60 million.
Sign-up for Arrowhead Prices At-Market Private Offering for $60 Million Net Proceeds investment picks
2014/3/3
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.
Sign-up for Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520 investment picks
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2013 fourth quarter and year ended September 30, 2013.
Sign-up for Arrowhead Reports Fiscal 2013 Fourth Quarter and Year-End Financial Results investment picks
2013/8/7
Arrowhead Research Corporation (NASDAQ: ARWR) , a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2013 third quarter ended June 30, 2013.
Sign-up for Arrowhead Reports Fiscal 2013 Third Quarter Financial Results investment picks
2014/2/4
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted therapeutics, today announced financial results for its fiscal 2014 first quarter ended December 31, 2013.
Sign-up for Arrowhead Reports Fiscal 2014 First Quarter Financial Results investment picks
2013/11/25
Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.
Sign-up for Arrowhead Submits Application to Begin Phase 2a Trial of ARC-520 for the Treatment of Chronic Hepatitis B Infection investment picks
2014/2/4
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that members of management will be panelists on two panel discussions at the 16 th Annual BIO CEO & Investor Conference on Monday, February 10, 2014.
Sign-up for Arrowhead to Participate in Panel Discussions at 16th Annual BIO CEO & Investor Conference investment picks
2014/3/10
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 8:00 a.m. EDT at the Loews Hotel in Miami, Florida.
Sign-up for Arrowhead to Present at Barclays Global Healthcare Conference investment picks
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the 25 th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4 at 1:30 p.m. EST at the New York Palace Hotel.
Sign-up for Arrowhead to Present at Piper Jaffray Healthcare Conference investment picks
2014/2/20
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at 3:30 p.m. EST at the New York Palace Hotel.
Sign-up for Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference investment picks
2013/10/18
Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on ARC-520, its hepatitis B drug candidate, at two upcoming scientific conferences.
Sign-up for Arrowhead to Present at Upcoming Conferences investment picks
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on the Dynamic Polyconjugate (DPC) siRNA delivery technology at two upcoming scientific conferences.
Sign-up for Arrowhead to Present at Upcoming Conferences investment picks
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2013 fourth quarter and year ended September 30, 2013, on Wednesday, December 18, 2013, at 4:30 p.m. Eastern time.
Sign-up for Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results investment picks
2013/7/31
Arrowhead Research Corporation (NASDAQ: ARWR) , a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2013 third quarter ended June 30, 2013, on Wednesday, August 7, 2013, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please dial 877-300-8521 (toll free from the US), 855-669-9657 (toll free from Canada), or 412-317-6026 (for international callers). Investors may also access a live audio webcast of this conference call on the Company's website at www.arrowheadresearch.com .
Sign-up for Arrowhead to Report Fiscal 2013 Third Quarter Financial Results investment picks
2014/1/28
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 first quarter ended December 31, 2013, on Tuesday, February 4, 2014, at 4:30 p.m. Eastern time.
Sign-up for Arrowhead to Report Fiscal 2014 First Quarter Financial Results investment picks
2014/3/11
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0932702001&sourceType=1 http://www.ccnmatthews.com/logos/20050930-arsenal.jpg CALGARY, ALBERTA --
Sign-up for Arsenal Energy Inc. Announces 2013 Fourth Quarter and Year End Results investment picks
2014/2/11
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0926924001&sourceType=1 http://www.ccnmatthews.com/logos/20050930-arsenal.jpg CALGARY, ALBERTA --
Sign-up for Arsenal Energy Inc. Declares Quarterly Dividend investment picks
2013/8/7
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0890852001&sourceType=1 http://www.ccnmatthews.com/logos/20050930-arsenal.jpg CALGARY, ALBERTA --
Sign-up for Arsenal Energy Releases Q2 Results and Announces Consolidation and Dividend investment picks
2013/11/14
ARMSTRONG, Iowa , Nov.
Sign-up for Art's Way Manufacturing Announces Cash Dividend On The Company's Common Stock investment picks
2014/4/9
Conference Call Scheduled For Monday, April 14, 2014 at 10:00 AM CT ARMSTRONG, Iowa , April 9, 2014 /PRNewswire/ -- Art's Way Manufacturing Co., Inc. (NASDAQ: ARTW) , announces a conference call for Monday, April 14, 2014 at 10:00 AM CT .
Sign-up for Art's Way Manufacturing Announces Conference Call To Review First Quarter 2014 Financial Results investment picks
The Contract Is Valued At Approximately $448,000. ARMSTRONG, Iowa , Aug.
Sign-up for Art's Way Manufacturing Announces Their Wholly Owned Subsidiary, Art's Way Scientific, Has Been Awarded A New Contract with A Leading Upper Midwest Dairy Operation For Three Modular Calf Care Buildings. investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Arrowhead Announces Pricing of Underwritten Offering of Common Stock to Art's Way Manufacturing Announces Their Wholly Owned Subsidiary, Art's Way Scientific, Has Been Awarded A New Contract with A Leading Upper Midwest Dairy Operation For Three Modular Calf Care Buildings.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity